Compare OPK & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | MDXG |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1995 | N/A |
| Metric | OPK | MDXG |
|---|---|---|
| Price | $1.35 | $7.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $2.28 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.8M | 774.9K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $642,067,000.00 | $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | $2.11 |
| P/E Ratio | ★ N/A | $26.77 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $1.11 | $5.79 |
| 52 Week High | $2.04 | $9.71 |
| Indicator | OPK | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 53.54 |
| Support Level | $1.28 | $6.62 |
| Resistance Level | $1.42 | $7.30 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 50.32 | 74.81 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.